Multiple Myeloma

Gareth J. Morgan, MD, PhD, discusses ongoing research of BCMA-targeted therapies, as well as the use of venetoclax in the myeloma treatment paradigm.

Marc J. Braunstein, MD, PhD, expands on the 3- and 4-drug regimens that are showing promise in the multiple myeloma paradigm.

Robb S. Friedman, MD, examines the developing role of venetoclax in relapsed/refractory multiple myeloma, based on the BELLINI results, and shares his anecdotal experience with the drug in the community setting.

Investigators have turned their attention to B-cell maturation antigen, which offers an ideal target for multiple myeloma therapy because of its restricted expression pattern.

Paul G. Richardson, MD, discusses the findings from the ICARIA-MM trial and the clinical implications of isatuximab’s FDA approval in multiple myeloma.

Noopur Raje, MD, discusses the utility of belantamab mafodotin in the treatment of patients with multiple myeloma.

Faith E. Davies, MD, discusses pivotal research in relapsed/refractory myeloma and precision medicine efforts in the field.

Betsy O’Donnell, MD, discusses unanswered questions in multiple myeloma.

James Weitzman, MD, discusses progress in the multiple myeloma treatment paradigm and what challenges remain.

Adam D. Cohen, MD, discusses the prospects for BCMA-targeting options in multiple myeloma.

Andrew Branagan, MD, discusses the research tandem transplants in patients with high-risk multiple myeloma.

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine at Harvard Medical School, discusses the FDA approval of isatuximab-irfc (Sarclisa) for use in combination with pomalidomide (Pomalyst) and dexamethasone in relapsed/refractory multiple myeloma.

Selinexor in combination with bortezomib and low-dose dexamethasone led to a statistically significant increase in progression-free survival compared with bortezomib/dexamethasone alone in patients with multiple myeloma who have received 1 to 3 prior lines of therapy.

The diagnosis and management of smoldering multiple myeloma is an area of tremendous focused research and change over the past decade, with trials yielding intriguing findings that have the potential to change practice.

Noopur Raje, MD, discusses the investigational CAR T-cell therapies and strategies in the multiple myeloma pipeline.

Sagar Lonial, MD, FACP, discusses how the treatment landscape has evolved for patients with smoldering multiple myeloma.

Andrew Yee, MD, reflects on recent clinical trials in multiple myeloma that focused on novel multidrug regimens.

Andrew Branagan, MD, discusses the evolving role of transplant and ongoing research in high-risk multiple myeloma.

Robb S. Friedman, MD, shares insight on the emergence of selinexor in the treatment paradigm for patients with relapsed/refractory multiple myeloma.

Shaji K. Kumar, MD, discusses the role of stem cell mobilization in multiple myeloma. This is important in patients with myeloma who are eligible for stem cell transplantation.

Jarrod Longcor, MS, MBA, discusses the potential utility of the small-molecule radiotherapeutic phospholipid-drug conjugate CLR 131 in patients with multiple myeloma.

Caitlin Costello, MD, discusses the future of isatuximab in relapsed/refractory multiple myeloma.

The foremost choice in the treatment of patients with newly diagnosed multiple myeloma is determining whether a patient is eligible for transplant, as that choice will set the stage for all future decisions.

Saad Z. Usmani, MD, FACP, discusses the need for immediate treatment intervention in patients with relapsed/refractory multiple myeloma.

Saad Z. Usmani, MD, expands on some of the key principles to inform the treatment of patients with relapsed/refractory multiple myeloma.